SCHEMBL172310

SCHEMBL172310

Oc1ncc(Cl)c(O)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.40
HPGD P15428 5/20 0.40
TSHR P16473 5/20 0.40
MAPK1 P28482 2/20 0.40
CASP1 P29466 1/20 0.38
CYP3A4 P08684 4/20 0.32
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 3/20 0.32
LMNA P02545 3/20 0.32
MAPT P10636 3/20 0.32
KMT2A Q03164 3/20 0.32
HSP90AA1 P07900 2/20 0.32
HTR1A P08908 2/20 0.32
ALOX15 P16050 2/20 0.32
ALOX12 P18054 2/20 0.32
SLC6A2 P23975 2/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALOX15B O15296 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688314 0.81 HPGD (0.36) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL5898805 0.81 HPGD (0.36) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL28710847 0.79 HPGD (0.35) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL28549014 0.79 HPGD (0.35) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL10513632 0.79 HPGD (0.35) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL10513635 0.79 HPGD (0.35) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL28550677 0.79 HPGD (0.35) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL28550675 0.79 HPGD (0.35) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL1701190 0.79 HSD17B10 (0.40) HSD17B10HPGDTSHRMAPK1CASP1
SCHEMBL135431 0.79 HSD17B10 (0.40) HSD17B10HPGDTSHRMAPK1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103360307-B Preparation method of 5-chloro-2,4-dihydroxypyridine NANJING LVYE PHARMACEUTICAL CO LTD 2015-05-06 CN disclosed
EP-1842847-B1 PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE TAIHO PHARMACEUTICAL CO LTD (JP) 2012-03-07 EP disclosed
US-7557216-B2 Process for production of 5-chloro-2,4-dihydroxypyridine TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-07 US disclosed
US-7557216-B2 Process for production of 5-chloro-2,4-dihydroxypyridine TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-07 US disclosed
US-20090043101-A1 PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-02-12 US disclosed
US-20090043101-A1 PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-02-12 US disclosed
US-5155113-A Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-10-13 US disclosed
EP-0180188-B1 A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed
EP-0137415-A2 Addition of polyhalonitriles to functionalized olefins THE DOW CHEMICAL COMPANY (US) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090043101-A1 PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE DPYD, DDT, HPD HSD17B10 200/4885HPGD 806/4885TSHR 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.